Back to search

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Data up to Jan 2025

Published2010
Citations1,307
References34

Total Citations Per Year

Abstract

References (34)

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

2017 • 12,167 citations

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 • 10,605 citations

Cancer Statistics, 2009

2009 • 9,675 citations

Revised Response Criteria for Malignant Lymphoma

2007 • 4,256 citations

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

2004 • 1,088 citations

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

2003 • 1,074 citations

Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

2003 • 831 citations

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

1992 • 654 citations

Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents

2006 • 462 citations

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy

1995 • 446 citations

High Expression of the CC Chemokine TARC in Reed-Sternberg Cells

1999 • 379 citations

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

2005 • 339 citations

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

2007 • 265 citations

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

2007 • 252 citations

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

2009 • 244 citations

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment

2006 • 232 citations

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

2005 • 214 citations

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma

2006 • 185 citations

Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.

2008 • 138 citations

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

2008 • 124 citations

Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

2008 • 119 citations

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

2005 • 112 citations

Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor

2005 • 105 citations

Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.

2000 • 88 citations

In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.

1995 • 82 citations

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

2007 • 73 citations

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

1998 • 68 citations

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

2009 • 59 citations

Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment In Vitro

2004 • 57 citations

Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma

2004 • 50 citations

Vinorelbine in the treatment of lymphoma

1998 • 31 citations

Vinorelbine in the treatment of lymphoma

1998 • 28 citations

Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s Disease

2005 • 14 citations

Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT.

2010 • 12 citations

Cited By (0)

No citing papers found in database

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas (2010) – New England Journal of Medicine | Metascience Observatory Explorer